Raised aldosterone to renin ratio predicts antihypertensive efficacy of spironolactone: a prospective cohort follow-up study
|
|
- Camron Tucker
- 5 years ago
- Views:
Transcription
1 Raised aldosterone to renin ratio predicts antihypertensive efficacy of spironolactone: a prospective cohort follow-up study P. O. Lim, R. T. Jung & T. M. MacDonald Hypertension Research Centre, Department of Clinical Pharmacology and Therapeutics, and Department of Endocrinology and Diabetes, Ninewells Hospital and Medical School, University of Dundee, Dundee, UK Aims Aldosterone/renin ratio is an index for inappropriate aldosterone activity, and it is increasingly being used to screen for primary aldosteronism within the hypertensive population. It may also be a good index to help predict the response to spironolactone. To assess the blood pressure response to oral spironolactone in hypertensive patients with primary aldosteronism identified with raised aldosterone to renin ratio. Methods We conducted a prospective cohort study of hypertensive patients with raised aldosterone/renin ratio, who failed to suppress plasma aldosterone with salt loading and fludrocortisone suppression test. These patients were treated with spironolactone and were followed-up for a period of up to 3 years. Results We studied 28 (12 male) subjects with a mean age of 55 (s.d. 10) years who were followed up for a mean period of 12.9 (7) months. At baseline, the patients were taking a mean of 2.1 (1.2) antihypertensive drugs, but despite this 16/28 (57%) had diastolic BP >90 mmhg, 39% with systolic BP >160 mmhg. After commencing spironolactone, three patients complained of breast tenderness but continued treatment and one patient was intolerant of spironolactone and had to stop treatment. Of the remaining 27 patients, the mean number of antihypertensive drugs used dropped to spironolactone plus 0.7 (s.d. 0.9). All but one patient (96%) achieved a diastolic BP 90 mmhg and 78% achieved a systolic BP 160 mmhg. In total 48% had BP 140/90 mmhg and 13/27 (48%) were treated with spironolactone monotherapy. Assessing only patients on drug treatment at baseline (n=24), spironolactone significantly reduced the need for antihypertensive drugs by 0.5 (CI ), P=0.02, as well as reducing blood pressure [systolic BP 15 mmhg (CI 5 25), P=0.007 and diastolic BP (mmhg) by 8 mmhg (CI 4 13), P=0.001]. Conclusions Spironolactone was a highly effective antihypertensive agent in hypertensive patients who had a raised aldosterone/renin ratio. As a raised ratio was highly predictive of nonsuppression of plasma aldosterone suggesting primary aldosteronism, it might be worthwhile using spironolactone in this subgroup of hypertensive patients with raised aldosterone/renin ratios, provided that adrenal adenomas are excluded with imaging techniques. Keywords: aldosterone/renin ratio, hypertension, primary aldosteronism, spironolactone Introduction The prevalence rate of primary aldosteronism is controversial but it may be more common than previously thought, accounting for up to 15% of clinic hypertensives Correspondence: Dr P. O. Lim, Hypertension Research Centre, Department of Clinical Pharmacology and Therapeutics, University of Dundee, Ninewells Hospital and Medical School, Dundee DD1 9SY, UK. Tel: +44(01382)632180, Fax: +44(01382)644972, pitt@clinpharm.dundee.ac.uk Received 16 April 1999, accepted 27 July [1 3]. We have recently reported that in a single GP practice, the prevalence of primary aldosteronism may be equally prevalent [4]. These studies utilized the aldosterone to plasma renin activity ratio (ARR) as a screening test. We believe that a raised ARR indicates inappropriate aldosterone activity, and we found that 94% of subjects with an ARR 750 failed to suppress plasma aldosterone with salt loading [3]. We have treated a cohort of these patients with oral spironolactone, and we report the response to this intervention. 756
2 Short report Methods Subjects Plasma renin activity (PRA) was measured using Biodata Renin MAIA assay (Serono Diagnostics Ltd, Woking, Surrey) with an intra-assay coefficient of variation of <10% between 0.3 and 18 ng ml 1 h 1, and a least detectable concentration of 0.3 mg ml 1 h 1. The interassay batch variation over a year was 11% (QC mean values 2.3 and 6.1 ng ml 1 h 1 ). Plasma aldosterone was measured using a solid-phase (coated tube) radioimmunoassay technique, DPC Coat- a-count assay (DPC, Llanberis, Caernarfon, Gwynedd) with an intra-assay coefficient of variation of <10% between 200 and 3300 pmol l 1, and a least detectable concentration of 70 pmol l 1 ). The interassay variation as calculated from QC pools run in each assay over a year was 10% (QC mean values 400 and 1050 pmol l 1 ). We screened for primary aldosteronism in all hypertensive patients referred for assessment in our Hypertension Research Centre in Tayside, using the ambulant plasma aldosterone (pmol ml 1 ) to plasma renin activity (ng ml 1 h 1 ) ratio of greater than or equal to 750 [3, 5] as our selection criteria (see below). Those subjects with a raised aldosterone to renin ratio were admitted for a standard salt loading and fludrocortisone suppression test (see below). Patients with a positive test (nonsuppress- ible serum aldosterone 140 pmol l 1 ) had adrenal CT scanning to screen for an adenoma. We also screened for glucocorticoid suppressible hyperaldosteronism (GSH) using genetic testing in patients who exhibited a drop in plasma aldosterone at h midday following salt loading. Patients without an adrenal adenoma on CT scanning and GSH on genetic testing were included in this follow-up cohort. Blood pressure measurements Seated blood pressure measurements were carried out using standard mercury sphygmomanometer in accordance to the British Hypertension Society guidelines. Salt loading and fludrocortisone suppression test Laboratory testing Intervention Subjects with raised ARR and a positive salt loading and fludrocortisone suppression test had oral spironolactone 50 mg once daily added to their usual antihypertensive regime. The first clinic visit was at 1 month, and subsequent duration between clinic visits varied between 4 weeks to 12 weeks at the discretion of the clinicians based on blood pressure responses and possible adverse effects. The usual antihypertensive drug treatment was withdrawn if blood pressure was 150/90 mmhg after the addition of spironolactone. The dose of spironolactone was reduced to 25 mg if adverse effects occurred or blood pressure normalized on a 50 mg monotherapy. The usual antihypertensive medications were withdrawn for between 7 and 10 days. None of these patients was on oral spironolactone which would require a more prolonged drug withdrawal period. Where necessary, an a-adrenoceptor blocker, doxasozin, was prescribed to Statistics control the blood pressure if the diastolic blood pressure was greater than or equal to 110 mmhg. All patients were routinely given two tablets of Slow-K (600 mg potassium chloride each) daily to avoid hypokalaemia. On day 1, each patient was given five Slow-Sodium (600 mg sodium chloride each) tablets at h and was defined at a P value of h following baseline supine h and ambulant h blood samplings for electrolytes, plasma cortisol Data are presented as mean (s.d.). Paired Student s t-test was used to assess the effect of spironolactone on the number of drugs used as well as its blood pressure lowering efficacy during follow-up. Statistical significance and aldosterone. On day 2, each patient was given four Results Slow-Sodium tablets with fludrocortisone 0.5 mg at We prospectively studied a cohort of 28 subjects ( h, and further Slow-Sodium tablets, five at h, males, mean age 55 years, s.d. 10) These patients were four at h and four at h. The day 2 regime followed up for a mean of 12.9 months (range was repeated on day 3. On day 4, the h treatment 3 35 months). Prior to spironolactone, the mean number regime was given following supine blood sampling, and of drugs the patients were taking was 2.1 (s.d. 1.2), the midday bloods were sampled following 4 h of despite which 16/28 (57%) had diastolic BP >90 mmhg ambulation at h. In total, 48 Slow-Sodium tablets (11/28) 39% with systolic BP >160 mmhg. One patient or mg of sodium chloride with 1.5 mg of could not tolerate spironolactone and had to stop fludrocortisone were given over a 4 day period. Patients the drug after 4 months of treatment (nonspecifically had their blood pressures carefully monitored throughout unwell). Of the remaining 27 patients, the mean the study period to identify possible complications. number of antihypertensive drugs required dropped to 757
3 P. O. Lim et al. spironolactone plus 0.7 (s.d. 0.9). All but one patient carcinoma in women [19], this link being tenuous bearing (96%) achieved a diastolic BP 90 mmhg and 78% in mind the high prevalence of this form of malignancy achieved a systolic BP 160 mmhg. In total 48% had a in the female population. In contrast to those studies BP 140/90 mmhg and 13/27 (48%) needed only performed in the late sixties and early seventies, we have spironolactone therapy (Table 1). used lower doses of spironolactone. This may explain the Table 2 shows that treatment with spironolactone relatively low incidence of adverse effects and the small significantly reduced antihypertensive drug treatment as dropout rate from our cohort. well as improving blood pressure control in patients who Based on our results, we believe that ARR may be an were on drug treatment at baseline. effective way of identifying hypertensive subjects who would respond to spironolactone who represent a Discussion significant proportion of the hypertensive population. We believe that there is now good evidence to mount a The favourable blood pressure lowering response to randomised trial of spironolactone vs other therapy in this spironolactone in this cohort of patients suggested that a group of patients. If our results are generalizable, and raised ARR was an effective index in identifying patients confirmed by further studies, our management strategy who would benefit from this drug treatment. About 60% has the potential to make a major impact on the of these patients were treated with nonspironolactone management of hypertension especially as about 1 in diuretics at baseline, and most of the remaining patients 10 hypertensives may fall into this subcategory. had had diuretics tried at some stage. Blood pressure control remained suboptimal however, suggesting that the favourable blood pressure response with spironolactone Limitations in our study was not related to its diuretic We do not think that regression to the mean explains effect alone. our results. Our patients had their blood pressures Our study has parallels with previous studies indicating measured for 3 6 months by their general practitioners a favourable response to spironolactone in subjects with before being labelled hypertensive, and were then referred low stimulated renin hypertension [6 8]. Further small to our hypertension clinic for assessment. Furthermore, scale studies however, revealed that other hypotensive the response to spironolactone was remarkable, in that agents (methydopa [9] and thiazide diuretics [10, 11]) nearly half the patients needed only spironolactone to were equally effective in low renin hypertensives, and control their hypertension. Previously, many of these this blood pressure lowering effects were not dependant patients needed three or more drugs to achieve blood on the renin status [12] (thiazide diuretics [11, 13], pressure control. However, we note that in six of the 27 nifedipine [14], and methydopa [9]). We believe that the patients who continued on spironolactone either systolic use of ARR is more specific than stimulated renin in or diastolic blood pressures or both were higher at the identifying primary aldosteronism, which forms the bulk follow-up, so this treatment is not uniformly effective in of mineralocorticoid related hypertension. We have all subjects. reported that the frusemide stimulation test, a commonly Our study is not free from the inherent biases of an used test to assess renin responsiveness had poor negative uncontrolled nonrandomized design, and the blood predictive value in screening for subjects with possible pressure measurements were carried out by at least three primary aldosteronism [15]. In other words, many subjects different individuals. However, the strength of our study with primary aldosteronism retain their renin responsive- is that it was carried out as part of routine clinical practice ness. In contrast, a raised ARR in our centre predicted and therefore relevant to day-to-day medical care of primary aldosteronism in 94% of subjects [3]. The finding hypertensive patients. We believe that our results point of hypertensive subjects with low renin and nonsuppressible to the need for a randomised controlled study to assess serum aldosterone is not new, and was described the response to spironolactone in this subgroup of about 20 years ago [16]. In our hands this test appears hypertensives. reasonably specific for primary aldosteronism if a ratio 750 is used. The use of spironolactone for treating essential Conclusions hypertension was curtailed in Britain following the Low dose spironolactone was highly effective in reducing Committee on Safety of Medicines (CSM) report in blood pressure in hypertensive patients with nonaden that it was associated with monomyelocytic leu- omatous primary aldosteronism identified with a raised kaemia in rats [17]. However, spironolactone has been aldosterone to renin ratio. Treatment with spironolactone used in humans for more than 30 years [18], with no significantly reduced the need for antihypertensive drug reported risk of malignancy apart from five cases of breast therapy. 758
4 759 Table 1 Anti-hypertensive treatment and blood pressure readings at baseline and during follow-up. Age Baseline Follow-up Last recorded clinic entry Patient (years) Sex Treatment SBP DBP (months) Treatment SBP DBP Comments 1 56 F Tenoretic Amlodipine 5, spiro F Atenolol Spiro M Amlodipine 5, bendrofluazide 2.5, atenolol Spiro 50, doxazosin 2 twice daily F Nil Spiro M Tenoretic 1, doxazosin Atenolol 50, spiro Breast tenderness 6 63 F Atenolol 50, dyazide 1, amlodipine Spiro M Sotalol 80 twice daily, bendrofluazide 2.5, Spiro 25, sotalol 40 twice daily, amlodipine 5 felodipine F Losartan 50, amlodipine 5, atenolol Atenolol 50, valsartan 80, Intolerant of spiro, last amlodipine 5 BP on spiro 180/ M Tenoretic 1, amlodipine Amlodipine 5, spiro Breast tenderness F Atenolol Spiro M Lisinopril 10, atenolol Lisinopril 10, amlodipine 5, spiro M Amlodipine Spiro 50, amlodipine F Lisinopril 40, amlodipine Spiro F Nil Spiro 50, atenolol F Atenolol 50, bendrofluazide Spiro M Atenolol 50, enalapril 10, amlodipine Spiro 50, atenolol M Bendrofluazide Spiro F Nil Spiro F Atenolol 50, amlodipine 10, Spiro lisinopril 20 twice daily, bendrofluazide M Bendrofluazide Spiro F Atenolol 50, amlodipine Spiro 50, amlodipine M Lisinopril 5, tenoretic Spiro 50, atenolol F Lisinopril 20, frusemide 40, Lisinopril 40, frusemide 40, bisoprolol 10, doxazosin 4 bisoprolol 10, doxazosin 4, spiro F Tenoretic Spiro M Atenolol 100, lisinopril 20, Spiro Breast tenderness frusemide 40, amlodipine F Nifedipine 10 SR Spiro F Atenolol 50, bendrofluazide Spiro 50, atenolol M Tenoretic Atenolol 50, spiro Short report
5 P. O. Lim et al. Table 2 Blood pressure lowering efficacy of spironolactone during follow-up. n=24* Baseline Follow-up** Outcome P value Number of antihypertensive agents used 2.3 (1.0) 1.8 (0.9) 0.5 (CI ) 0.02 Systolic blood pressure (mmhg) 161 (15) 146 (21) 15 (CI 5 25) Diastolic blood pressure (mmhg) 91 (9) 83 (7) 8 (CI 4 13) *Excluding cases 4, 14, and 18 who were untreated at baseline, and case 8 who could not tolerate spironolactone. **Including spironolactone. We thank Margaret Coull for her secretarial assistance. All authors normal renin hypertension. Act Med Scand 1975; 197: were jointly involved in the design and implementation of the study. All authors contributed to writing the paper. 10 Adlin EV, Marks AD, Channick BJ. Spironolactone and hydrochlorothiazide in essential hypertension. Blood pressure response and plasma renin activity. Arch Intern Med 1972; References 130: Gordon RD. Mineralocorticoid hypertension. Lancet 1994; 11 Ferguson RK, Turek DM, Rovner DR. Spironolactone and 344: hydrochlorothiazide in normal-renin and low-renin essential 2 Anis Anwar Y, White WB, Mansoor GA, et al. hypertension. Clin Pharmacol Ther 1977; 21: Hyperaldosteronism is a common cause of secondary 12 Sundsf jord JA, Odegaard AE. Renin levels and hypertension missed by primary care physicians and spironolactone treatment in general practice: similar blood associated with normokalaemia. Am J Hypertens 1998; 11 pressure lowering effect of spironolactone in low and normal (4 part; 2): 199A (M001). renin patients. Eur J Clin Invest 1977; 7: Lim PO, Brennan G, Shiels P, et al. Unexpectedly high 13 Drayer JI, Kloppenborg PW, Festen J, et al. Intrapatient prevalence of primary aldosteronism in a hypertensive comparison of treatment with chlorthalidone, spironolactone population in Dundee. J Endocrinol 1998; 156(Suppl): P22. and propranolol in normoreninemic essential hypertension. 4 Lim PO, Rodgers P, Cardale K, et al. Potentially high Am J Cardiol 1975; 36: prevalence of primary aldosteronism in a primary-care 14 Henry M, Wehrlen M, Pelletier B, et al. Spironolactone population. Lancet 1999; 353: 40. versus nifedipine in essential hypertension. Am J Cardiol 5 Gordon RD, Stowasser M, Klemm SA, et al. Primary 1990; 65: 36K 38K. aldosteronism and other forms of mineralocorticoid 15 Lim PO, Brennan GM, Jung RT, et al. Diagnosing primary hypertension. In Textbook of Hypertension, ed. Swales J. aldosteronism with frusemide stimulation test in hypertensive Oxford: Blackwell Scientific, 1994: patients with raised aldosterone to renin ratio. Med Biochem 6 Carey RM, Douglas JG, Schweikert JR, et al. The syndrome 1999 in press. of essential hypertension and suppressed plasma renin 16 Helber A, Wambach G, Hummerich W, et al. Evidence for activity. Normalization of blood pressure with a subgroup of essential hypertensives with non-suppressible spironolactone. Arch Intern Med 1972; 130: excretion of aldosterone during sodium loading. Klin 7 Spark RF, Melby JC. Hypertension and low plasma renin Wochenschr 1980; 58: activity: presumptive evidence for mineralocorticoid excess. 17 Anonymous. Spironolactone: no longer for hypertension. Ann Intern Med 1971; 75: Drug Ther Bull 1988; 26: Karlberg BE, Kagedal B, Tegler L, et al. Renin 18 Takeda R, Yamazaki T, Ito Y, et al. Twenty-four year concentrations and effects of propranolol and spironolactone spironolactone therapy in an aged patient with aldosterone- in patients with hypertension. Br Med J 1976; 1: producing adenoma. Acta Endocrinol 1992; 126: Solheim SB, Sundsf jord JA, Giezendanner L. The effect of 19 McInnes GT. Diuretics. In Meyler s Side Effects of Drugs 13, spironolactone (Aldactone) and methyldopa in low and ed. Dukes MNG. Amsterdam: Elsevier, 1996:
Is aldosterone the missing link in refractory hypertension?: aldosterone-torenin ratio as a marker of inappropriate aldosterone activity
(2002) 16, 153 158 2002 Nature Publishing Group All rights reserved 0950-9240/02 $25.00 www.nature.com/jhh REVIEW ARTICLE Is aldosterone the missing link in refractory hypertension?: aldosterone-torenin
More informationAbout 20% of the Canadian population
Mineralocorticoid Hypertension: Common and Treatable Hypertension is the most common chronic disease treated by the primary-care physician. It is now evident that mineralocorticoid hypertension, which
More informationYounger adults with a family history of premature artherosclerotic disease should have their cardiovascular risk factors measured.
Appendix 2A - Guidance on Management of Hypertension Measurement of blood pressure All adults from 40 years should have blood pressure measured as part of opportunistic cardiovascular risk assessment.
More informationResistant hypertension, defined as a failure of concomitant. Efficacy of Low-Dose Spironolactone in Subjects With Resistant Hypertension
AJH 2003; 16:925 930 Efficacy of Low-Dose Spironolactone in Subjects With Resistant Hypertension Mari Konishi Nishizaka, Mohammad Amin Zaman, and David A. Calhoun Background: Previous reports have demonstrated
More informationManagement of Hypertension
Clinical Practice Guidelines Management of Hypertension Definition and classification of blood pressure levels (mmhg) Category Systolic Diastolic Normal
More informationDr Diana R Holdright. MD, FRCP, FESC, FACC, MBBS, DA, BSc. Consultant Cardiologist HYPERTENSION.
Dr Diana R Holdright MD, FRCP, FESC, FACC, MBBS, DA, BSc. Consultant Cardiologist HYPERTENSION www.drholdright.co.uk Blood pressure is the pressure exerted on the walls of the arteries when the heart pumps;
More informationPrimary Aldosteronism
Primary Aldosteronism Odelia Cooper, MD Assistant Professor of Medicine Division of Endocrinology, Diabetes, and Metabolism Cedars-Sinai Medical Center HYPERTENSION CENTER Barriers to diagnosing primary
More informationSTANDARD treatment algorithm mmHg
STANDARD treatment algorithm 130-140mmHg (i) At BASELINE, If AVERAGE SBP 1 > 140mmHg If on no antihypertensive drugs: Start 1 drug: If >55 years old / Afro-Caribbean: Calcium channel blocker (CCB) 2 If
More informationDifficult-to-Control & Resistant Hypertension. Anthony Viera, MD, MPH, FAHA Professor and Chair
Difficult-to-Control & Resistant Hypertension Anthony Viera, MD, MPH, FAHA Professor and Chair Objectives Define resistant hypertension Discuss evaluation strategy for patient with HTN that appears difficult
More informationHypertension Update 2009
Hypertension Update 2009 New Drugs, New Goals, New Approaches, New Lessons from Clinical Trials Timothy C Fagan, MD, FACP Professor Emeritus University of Arizona New Drugs Direct Renin Inhibitors Endothelin
More informationHypertension Update Clinical Controversies Regarding Age and Race
Hypertension Update Clinical Controversies Regarding Age and Race Allison Helmer, PharmD, BCACP Assistant Clinical Professor Auburn University Harrison School of Pharmacy July 22, 2017 DISCLOSURE/CONFLICT
More informationPrimary Aldosteronism: screening, diagnosis and therapy
Primary Aldosteronism: screening, diagnosis and therapy Jacques W.M. Lenders, internist DEPT. OF INTERNAL MEDICINE, RADBOUD UNIVERSITY NIJMEGEN MEDICAL CENTER, NIJMEGEN,THE NETHERLANDS DEPT. OF INTERNAL
More informationBy Prof. Khaled El-Rabat
What is The Optimum? By Prof. Khaled El-Rabat Professor of Cardiology - Benha Faculty of Medicine HT. Introduction Despite major worldwide efforts over recent decades directed at diagnosing and treating
More informationClarification of hypertension Diagnosis of primary hyperaldosteronism
Nr. 1/2010 Clarification of hypertension Diagnosis of primary hyperaldosteronism Marc Beineke The significance of the /renin ratio (ARR) in the diagnosis of normoalaemic and hypokalaemic primary hyperaldosteronism,
More informationFelodipine vs hydralazine: a controlled trial as third line therapy
Br. J. clin. Pharmac. (1986), 21, 621-626 Felodipine vs hydralazine: a controlled trial as third line therapy in hypertension CO-OPERATIVE STUDY GROUP* *Members of the co-operative study group were: Responsible
More informationManaging hypertension: a question of STRATHE
(2005) 19, S3 S7 & 2005 Nature Publishing Group All rights reserved 0950-9240/05 $30.00 www.nature.com/jhh ORIGINAL ARTICLE Managing hypertension: a question of STRATHE Department of Cardiovascular Disease,
More informationChapter 2 ~ Cardiovascular system
Chapter 2 ~ Cardiovascular System: General Section 1 of 6 Chapter 2 ~ Cardiovascular system 2.1 Positive inotropic drugs 2.1.1 Cardiac glycosides DIGOXIN 2.2 Diuretics Elixir 50micrograms in 1ml Injection
More informationUpdates in primary hyperaldosteronism and the rule
Updates in primary hyperaldosteronism and the 20-50 rule I. David Weiner, M.D. Professor of Medicine and Physiology and Functional Genomics University of Florida College of Medicine and NF/SGVHS The 20-50
More informationHow well do office and exercise blood pressures predict sustained hypertension? A Dundee Step Test Study
(2000) 14, 429 433 2000 Macmillan Publishers Ltd All rights reserved 0950-9240/00 $15.00 www.nature.com/jhh ORIGINAL ARTICLE How well do office and exercise blood pressures predict sustained hypertension?
More informationLABETALOL IN SEVERE AND RESISTANT HYPERTENSION
Br. J. clin. Pharmac. (1979), 8, 13S-17S LABETALOL IN SEVERE AND RESISTANT HYPERTENSION King's College Hospital Renal Unit, Dulwich Hospital, London SE22 8PT, UK 1 The efficacy of labetalol in the treatment
More informationHigh-dose monotherapy vs low-dose combination therapy of calcium channel blockers and angiotensin receptor blockers in mild to moderate hypertension
(2005) 19, 491 496 & 2005 Nature Publishing Group All rights reserved 0950-9240/05 $30.00 www.nature.com/jhh ORIGINAL ARTICLE High-dose monotherapy vs low-dose combination therapy of calcium channel blockers
More informationOutpatient Fludrocortisone Suppression Test: A Safe and Effective Alternative to Inpatient
Outpatient Fludrocortisone Suppression Test: A Safe and Effective Alternative to Inpatient Testing/ Original Article Author Information Dr Walter van der Merwe MBChB, FRACP, Consultant Nephrologist, Renal
More informationMODERN MANAGEMENT OF HYPERTENSION Where Do We Draw the Line? Disclosure. No relevant financial relationships. Blood Pressure and Risk
MODERN MANAGEMENT OF HYPERTENSION Where Do We Draw the Line? Disclosure No relevant financial relationships Robert B. Baron, MD MS Professor and Associate Dean UCSF School of Medicine baron@medicine.ucsf.edu
More informationUpdates in primary hyperaldosteronism and the rule
Updates in primary hyperaldosteronism and the 20-50 rule I. David Weiner, M.D. C. Craig and Audrae Tisher Chair in Nephrology Professor of Medicine and Physiology and Functional Genomics University of
More informationIntroductory Clinical Pharmacology Chapter 41 Antihypertensive Drugs
Introductory Clinical Pharmacology Chapter 41 Antihypertensive Drugs Blood Pressure Normal = sys
More informationBest Therapy for Resistant Hypertension: The PATHWAY-2 2 Study
Best Therapy for Resistant Hypertension: The PATHWAY-2 2 Study Antonio Coca MD, PhD, FRCP, FESC Council on Hypertension. European Society of Cardiology Hypertension and Vascular Risk Unit. Department of
More informationManaging Hypertension in 2016
Managing Hypertension in 2016: Where Do We Draw the Line? Disclosure No relevant financial relationships Robert B. Baron MD MS Professor and Associate Dean UCSF School of Medicine baron@medicine.ucsf.edu
More informationHypertension. Does it Matter What Medications We Use? Nishant K. Sekaran, M.D. M.Sc. Intermountain Heart Institute
Hypertension Does it Matter What Medications We Use? Nishant K. Sekaran, M.D. M.Sc. Intermountain Heart Institute Hypertension 2017 Classification BP Category Systolic Diastolic Normal 120 and 80 Elevated
More informationPrimary aldosteronism clinical practice guidelines: a re-appraisal The Management of Primary Aldosteronism
Primary aldosteronism clinical practice guidelines: a re-appraisal The Management of Primary Aldosteronism Prof. FRANCO MANTERO Division of Endocrinology University of Padua Italy Case Detection, Diagnosis
More informationHypertension Guidelines: Are We Pressured to Change? Oregon Cardiovascular Symposium Portland, Oregon June 6, Financial Disclosures
Hypertension Guidelines: Are We Pressured to Change? Oregon Cardiovascular Symposium Portland, Oregon June 6, 2015 William C. Cushman, MD Professor, Preventive Medicine, Medicine, and Physiology University
More informationANTI- HYPERTENSIVE AGENTS
CLINICAL ANTI- HYPERTENSIVE AGENTS Jacqueline van Schoor, MPharm, BSc (Hons) Amayeza Info Centre Hypertension represents a major public health concern. It affects about a billion people worldwide and is
More informationVolume 6; Number 1 January 2012 NICE CLINICAL GUIDELINE 127: HYPERTENSION CLINICAL MANAGEMENT OF PRIMARY HYPERTENSION IN ADULTS (AUGUST 2011)
Volume 6; Number 1 January 2012 NICE CLINICAL GUIDELINE 127: HYPERTENSION CLINICAL MANAGEMENT OF PRIMARY HYPERTENSION IN ADULTS (AUGUST 2011) What s new in hypertension? NICE has issued an updated Clinical
More informationAdapted d from Federation of Health Regulatory Colleges of Ontario Template Last Updated September 18, 2017
Insert Logo or Org Name Here Primary Care Medical Directive for Hypertension Management Adapted d from Federation of Health Regulatory Colleges of Ontario Template Last Updated September 18, 2017 Title:
More informationAPPENDIX D: PHARMACOTYHERAPY EVIDENCE
Página 1 de 7 APPENDIX D: PHARMACOTYHERAPY EVIDENCE Table D1. Outcome Trials of Antihypertensive Agents Study Drug Regimen N Duration Primary Outcomes Remarks Antihypertensive Therapy vs Placebo SHEP 1991
More informationpotassium ratio and response to diuretics in
Postgraduate Medical Journal (March 1977) 53, 117-121. Nineteen patients The urinary sodium : potassium ratio and response to diuretics in resistant oedema WILLIAM D. ALEXANDER* D. F. LEVINE R. A. BRANCHt
More informationPrevalence of primary hyperaldosteronism assessed by aldosterone/renin ratio and spironolactone testing
ORIGINAL PAPERS Prevalence of primary hyperaldosteronism assessed by aldosterone/renin ratio and spironolactone testing Sue Hood, John Cannon, Roger Foo and Morris Brown ABSTRACT Recent studies have suggested
More informationHypertension 2015: Recent Evidence that Will Change Your Practice
Hypertension 2015: Recent Evidence that Will Change Your Practice Gerald W. Smetana, M.D. Division of General Medicine Beth Israel Deaconess Medical Center Professor of Medicine Harvard Medical School
More informationAdult Blood Pressure Clinician Guide June 2018
Kaiser Permanente National CLINICAL PRACTICE GUIDELINES Adult Blood Pressure Clinician Guide June 2018 Adult Blood Pressure Clinician Guide June 2018 Introduction This Clinician Guide is based on the 2018
More informationHYPERTENSION IN THE ELDERLY A BALANCED APPROACH. Barry Goldlist October 31, 2014
HYPERTENSION IN THE ELDERLY A BALANCED APPROACH Barry Goldlist October 31, 2014 DISCLOSURE I have not accepted any money for myself from any pharmaceutical company in the 21 st century I have accepted
More informationHypertension diagnosis (see detail document) Diabetic. Target less than 130/80mmHg
Hypertension diagnosis (see detail document) Non-diabetic Diabetic Very elderly (older than 80 years) Target less than 140/90mmHg Target less than 130/80mmHg Consider SBP target less than 150mmHg Non-diabetic
More informationOverview of the outcome trials in older patients with isolated systolic hypertension
Journal of Human Hypertension (1999) 13, 859 863 1999 Stockton Press. All rights reserved 0950-9240/99 $15.00 http://www.stockton-press.co.uk/jhh Overview of the outcome trials in older patients with isolated
More informationACE. Inhibitors. Quiz feedback
ACE Inhibitors Quiz feedback bpac nz better medicin e bpac nz Quiz feedback, ACE inhibitors, 2006 Best Practice Advocacy Centre ACE inhibitors quiz feedback bpac nz Development Team: Rachael Clarke Sonia
More informationCOMPLEX HYPERTENSION. Anita Ralstin, FNP-BC Next Step Health Consultant, LLC
COMPLEX HYPERTENSION Anita Ralstin, FNP-BC Next Step Health Consultant, LLC Incidence Of Hypertension About 70 million American adults have high blood pressure. About 33% of the population Only 52% have
More informationPhase 3 investigation of aprocitentan for resistant hypertension management. Investor Webcast June 2018
Phase 3 investigation of aprocitentan for resistant hypertension management Investor Webcast June 2018 The following information contains certain forward-looking statements, relating to the company s business,
More informationHeart Failure Clinician Guide JANUARY 2018
Kaiser Permanente National CLINICAL PRACTICE GUIDELINES Heart Failure Clinician Guide JANUARY 2018 Introduction This evidence-based guideline summary is based on the 2018 National Heart Failure Guideline.
More informationTreating Hypertension in Individuals with Diabetes
Treating Hypertension in Individuals with Diabetes Copyright 2017 by Sea Courses Inc. All rights reserved. No part of this document may be reproduced, copied, stored, or transmitted in any form or by any
More informationAntihypertensive efficacy of olmesartan compared with other antihypertensive drugs
(2002) 16 (Suppl 2), S24 S28 2002 Nature Publishing Group All rights reserved 0950-9240/02 $25.00 www.nature.com/jhh compared with other antihypertensive drugs University Clinic Bonn, Department of Internal
More informationWill the recent hypertension trials change the guidelines?
710891JRA0010.1177/1470320317710891Journal of the Renin-Angiotensin-Aldosterone SystemSever research-article2017 Commentary Will the recent hypertension trials change the guidelines? Journal of the Renin-Angiotensin-
More informationALLHAT. Major Outcomes in High Risk Hypertensive Patients Randomized to Angiotensin-Converting Enzyme Inhibitor or Calcium Channel Blocker vs Diuretic
1 U.S. Department of Health and Human Services National Institutes of Health Major Outcomes in High Risk Hypertensive Patients Randomized to Angiotensin-Converting Enzyme Inhibitor or Calcium Channel Blocker
More informationA double-blind comparison of bisoprolol and atenolol in patients with essential hypertension
QJ Med 995; 88:55-5 A double-blind comparison of bisoprolol and atenolol in patients with essential hypertension N.M. WHEELDON, T.M. MacDONALD, N. PRASAD, D. MACLEAN, L. PEEBLES and D.G. McDEVITT From
More informationHypertension and Cardiovascular Disease
Hypertension and Cardiovascular Disease Copyright 2017 by Sea Courses Inc. All rights reserved. No part of this document may be reproduced, copied, stored, or transmitted in any form or by any means graphic,
More informationHypertension Pharmacotherapy: A Practical Approach
Hypertension Pharmacotherapy: A Practical Approach Ronald Victor, MD Burns & Allen Chair in Cardiology Director, The Hypertension Center Associate Director, The Heart Institute Hypertension Center 1. 2.
More informationManagement of Hypertension and Consequences of non-compliance. Colin Edwards
Management of Hypertension and Consequences of non-compliance Colin Edwards CARDIOLOGIST AHG May 2016 Outline 1. Consequences of poorly controlled hypertension 2. BP targets and anti-hypertensive drugs
More informationJared Moore, MD, FACP
Hypertension 101 Jared Moore, MD, FACP Assistant Program Director, Internal Medicine Residency Clinical Assistant Professor of Internal Medicine Division of General Medicine The Ohio State University Wexner
More informationACEBUTOLOL HCL 100MG TABLET GENERIC BETA BLOCKERS ALISKIREN 150MG TABLET RASILAZ RENIN INHIBITOR
S/N ME OF MEDICATIONS BRANDED/GENERIC DRUG CLASS * UNIT PRICE RANGE (SGD$) 1 ACEBUTOLOL HCL 100MG CAPSULE SECTRAL BETA BLOCKERS 0.50 2 ACEBUTOLOL HCL 100MG TABLET GENERIC BETA BLOCKERS 0.33 3 ALISKIREN
More informationHEART FAILURE SUMMARY. and is associated with significant morbidity and mortality. the cornerstone of heart failure treatment.
HEART FAILURE SUMMARY + Heart Failure is a condition affecting a large number of Irish people and is associated with significant morbidity and mortality. + ACE inhibitors, in combination with diuretics,
More informationDr Narender Goel MD (Internal Medicine and Nephrology) Financial Disclosure: None, Conflict of Interest: None
Dr Narender Goel MD (Internal Medicine and Nephrology) drnarendergoel@gmail.com Financial Disclosure: None, Conflict of Interest: None 12 th December 2013, New York Visit us at: http://kidneyscience.info/
More informationAntihypertensive Combinations
This Professional Resource gives subscribers additional insight related to the Recommendations published in PHARMACIST S LETTER / PRESCRIBER S LETTER October 2016 ~ Resource #321047 Antihypertensive Combinations
More informationHypertension Management: A Moving Target
9:45 :30am Hypertension Management: A Moving Target SPEAKER Karol Watson, MD, PhD, FACC Presenter Disclosure Information The following relationships exist related to this presentation: Karol E. Watson,
More informationOutcomes and Perspectives of Single-Pill Combination Therapy for the modern management of hypertension
Outcomes and Perspectives of Single-Pill Combination Therapy for the modern management of hypertension Prof. Massimo Volpe, MD, FAHA, FESC, Chair of Cardiology, Department of Clinical and Molecular Medicine
More informationHeart Failure Clinician Guide JANUARY 2016
Kaiser Permanente National CLINICAL PRACTICE GUIDELINES Heart Failure Clinician Guide JANUARY 2016 Introduction This evidence-based guideline summary is based on the 2016 National Heart Failure Guideline.
More informationRESISTENT HYPERTENSION. Dr. Helmy Bakr Professor and Head of Cardiology Dept. Mansoura University
RESISTENT HYPERTENSION Dr. Helmy Bakr Professor and Head of Cardiology Dept. Mansoura University Resistant Hypertension Blood pressure remaining above goal in spite of concurrent use of 3 antihypertensive
More informationState of the art treatment of hypertension: established and new drugs. Prof. M. Burnier Service of Nephrology and Hypertension Lausanne, Switzerland
State of the art treatment of hypertension: established and new drugs Prof. M. Burnier Service of Nephrology and Hypertension Lausanne, Switzerland First line therapies in hypertension ACE inhibitors AT
More informationYear 2004 Paper two: Questions supplied by Megan 1
Year 2004 Paper two: Questions supplied by Megan 1 QUESTION 96 A 32yo woman if found to have high blood pressure (180/105mmHg) at an insurance medical examination. She is asymptomatic. Clinical examination
More informationThe legally binding text is the original French version TRANSPARENCY COMMITTEE OPINION. 7 January 2009
The legally binding text is the original French version TRANSPARENCY COMMITTEE OPINION 7 January 2009 LERCAPRESS 10 mg/10 mg, film-coated tablets Pack of 30 (CIP code: 385 953-3) Pack of 90 (CIP code:
More informationHypertension Management - Summary
Who should have blood pressure assessed? Hypertension Management - Summary All patients over the age of 40 years, every 1-3 years in order to determine their cardiovascular risk (ie. Framingham Risk Score)
More information1. Despite the plethora of new ACE-inhibitors they offer little advantage over the earlier products captopril and enalapril.
SUMMARY 1. Despite the plethora of new ACE-inhibitors they offer little advantage over the earlier products captopril and enalapril. 2. While diuretics and beta-blockers remain first-line antihypertensive
More informationPractical Aspects of Hypertension: Simple Strategies to Help You and Your Patients Meet Guideline Blood Pressure Targets
Practical Aspects of Hypertension: Simple Strategies to Help You and Your Patients Meet Guideline Blood Pressure Targets Robert J. Herman University of Calgary herman@ucalgary.ca Conflict of Interest Disclosure
More informationAntihypertensive Drug Procurement Trends from 1995 to 2004: Transition over a Decade. Khalid AJ Al Khaja, PhD*
1 Bahrain Medical Bulletin, Vol. 34, No. 2, June 2012 Antihypertensive Drug Procurement Trends from 1995 to 2004: Transition over a Decade Khalid AJ Al Khaja, PhD* Objective: To evaluate antihypertensive
More informationHypertension (JNC-8)
Hypertension (JNC-8) Southern California University of Health Sciences Physician Assistant Program Management and Treatment of Hypertension April 17, 2018, presented by Ezra Levy, Pharm.D.! The 8 th Joint
More informationJNC 8 -Controversies. Sagren Naidoo Nephrologist CMJAH
JNC 8 -Controversies Sagren Naidoo Nephrologist CMJAH Joint National Committee (JNC) Panel appointed by the National Heart, Lung, and Blood Institute (NHLBI) First guidelines (JNC-1) published in 1977
More informationHypertensionTreatment Guidelines. Michaelene Urban APRN, MSN, ACNS-BC, ANP-BC
HypertensionTreatment Guidelines Michaelene Urban APRN, MSN, ACNS-BC, ANP-BC Objectives: Review the definition of the different stages of HTN. Review the current guidelines for treatment of HTN. Provided
More informationNew Antihypertensive Strategies to Improve Blood Pressure Control
New Antihypertensive Strategies to Improve Blood Pressure Control Antonio Coca, MD, PhD,, FRCP, FESC Hypertension and Vascular Risk Unit Department of Internal Medicine. Hospital Clínic (IDIBAPS) University
More informationNetwork Hypertension Algorithm
Network Hypertension Algorithm Content Review and Approval: This document is subject to review, revision, and (re)approval by the Clinical Integration and Oversight Committee (CIOC) annually and following
More informationEndocrine. Endocrine as it relates to the kidney. Sarah Elfering, MD University of Minnesota
Endocrine Sarah Elfering, MD University of Minnesota Endocrine as it relates to the kidney Parathyroid gland Vitamin D Endocrine causes of HTN Adrenal adenoma PTH Bone Kidney Intestine 1, 25 OH Vitamin
More information12.5mg, 25mg, 50mg. 25mg, 50mg. 2.5mg, 5mg, 10mg. 5mg, 10mg, 20mg, 100mg. 25mg. -- $2.81 Acetazolamide (IR, 125mg, 250mg, 500mg (ER)
MEDICATION COVERAGE POLICY PHARMACY AND THERAPEUTICS ADVISORY COMMITTEE POLICY: Blood Pressure P&T DATE: 5/9/2017 THERAPEUTIC CLASS: Cardiovascular Disorders REVIEW HISTORY: 9/15, 2/13, 2/08, 5/07 LOB
More informationDISCLOSURES OUTLINE OUTLINE 9/29/2014 ANTI-HYPERTENSIVE MANAGEMENT OF CHRONIC KIDNEY DISEASE
ANTI-HYPERTENSIVE MANAGEMENT OF CHRONIC KIDNEY DISEASE DISCLOSURES Editor-in-Chief- Nephrology- UpToDate- (Wolters Klewer) Richard J. Glassock, MD, MACP Geffen School of Medicine at UCLA 1 st Annual Internal
More informationHYPERTENSION CHAT with Colin and Ted AUG 2015
HYPERTENSION CHAT with Colin and Ted AUG 2015 INTRODUCTION Hypertension has challenged famous physicians for centuries. 1733 - Clergyman Stephen Hales made the 1 st published measurement of blood pressure
More informationALLHAT RENAL DISEASE OUTCOMES IN HYPERTENSIVE PATIENTS STRATIFIED INTO 4 GROUPS BY BASELINE GLOMERULAR FILTRATION RATE (GFR)
1 RENAL DISEASE OUTCOMES IN HYPERTENSIVE PATIENTS STRATIFIED INTO 4 GROUPS BY BASELINE GLOMERULAR FILTRATION RATE (GFR) 6 / 5 / 1006-1 2 Introduction Hypertension is the second most common cause of end-stage
More informationHypertension and the 2017 Guidelines Meeting the Targets in Small Groups. Lisa Ivy APRN
Hypertension and the 2017 Guidelines Meeting the Targets in Small Groups Lisa Ivy APRN The 2017 Guideline is an Update to JNC7 New information regarding BP related risk of CVD Ambulatory BP monitoring
More informationHigh blood pressure (Hypertension)
High blood pressure (Hypertension) Information for patients from the Department of Renal (Kidney) Medicine This leaflet is not meant to replace the information discussed between you and your doctor, but
More informationMetoprolol Succinate SelokenZOC
Metoprolol Succinate SelokenZOC Blood Pressure Control and Far Beyond Mohamed Abdel Ghany World Health Organization - Noncommunicable Diseases (NCD) Country Profiles, 2014. 1 Death Rates From Ischemic
More informationHypertension Putting the Guidelines into Practice
Hypertension 2017 Putting the Guidelines into Practice Disclosures Relationships with commercial interests: Grants/Research Support: Speakers Bureau/Honoraria: Consulting Fees: Data Safety and Monitoring:
More informationHypertension Update Warwick Jaffe Interventional Cardiologist Ascot Hospital
Hypertension Update 2008 Warwick Jaffe Interventional Cardiologist Ascot Hospital Definition of Hypertension Continuous variable At some point the risk becomes high enough to justify treatment Treatment
More informationHow to Manage Resistant Hypertension Min Su Hyon, MD
How to Manage Resistant Hypertension Min Su Hyon, MD Cardiovascular Medicine, Internal Medicine Soonchunhyang University College of Medicine Definition Resistant to conventional medical therapy Definition
More informationHYPERTENSION GUIDELINES WHERE ARE WE IN 2014
HYPERTENSION GUIDELINES WHERE ARE WE IN 2014 Donald J. DiPette MD FACP Special Assistant to the Provost for Health Affairs Distinguished Health Sciences Professor University of South Carolina University
More informationHypertension Putting the Guidelines into Practice
Hypertension 2017 Putting the Guidelines into Practice Copyright 2017 by Sea Courses Inc. All rights reserved. No part of this document may be reproduced, copied, stored, or transmitted in any form or
More informationHyperaldosteronism: recent concepts, diagnosis, and management
Postgrad Med J 2001;77:639 644 639 Clinical Pharmacology Unit, University of Cambridge, Box 110, Addenbrooke s Hospital, Cambridge CB2 2QQ, UK RFoo K M O Shaughnessy M J Brown Correspondence to: Dr Foo
More informationDECLARATION OF CONFLICT OF INTEREST
DECLARATION OF CONFLICT OF INTEREST Novel approaches in hypertension Aldosterone-synthase inhibitors. Faiez Zannad Nancy, France Disclosures Dr Zannad reports receiving Speaker/consultant honoraria from
More informationModern Management of Hypertension
Modern Management of Hypertension Robert B. Baron MD Professor of Medicine Associate Dean for GME and CME Declaration of full disclosure: No conflict of interest Current Status of Hypertension Prevalence
More informationFactors Involved in Poor Control of Risk Factors
Factors Involved in Poor Control of Risk Factors Patient compliance Clinical inertia Health Care System structure 14781 M Limitations of Formal Studies Selection of patients Recruitment and follow-up alter
More informationDrug-Induced Diabetes May Not Be Harmful But Should Be Prevented. Jeffrey A. Cutler, MD, MPH
Drug-Induced Diabetes May Not Be Harmful But Should Be Prevented Jeffrey A. Cutler, MD, MPH Overview Focus on thiazide-like diuretics (not BB) Diuretic-induced versus diureticassociated diabetes Role of
More informationHypertension in the Elderly. John Puxty Division of Geriatrics Center for Studies in Aging and Health, Providence Care
Hypertension in the Elderly John Puxty Division of Geriatrics Center for Studies in Aging and Health, Providence Care Learning Objectives Review evidence for treatment of hypertension in elderly Consider
More informationThe legally binding text is the original French version TRANSPARENCY COMMITTEE OPINION. 9 March 2011
The legally binding text is the original French version TRANSPARENCY COMMITTEE OPINION 9 March 2011 TAREG 3 mg/ml oral solution B/1 160 ml (CIP code: 491 474-8) Applicant: NOVARTIS PHARMA SAS valsartan
More informationThe legally binding text is the original French version TRANSPARENCY COMMITTEE OPINION. 27 May 2009
The legally binding text is the original French version TRANSPARENCY COMMITTEE OPINION 27 May 2009 RASILEZ HCT 150 mg/12.5 mg, film-coated tablets B/30 (CIP code: 392 151-6) RASILEZ HCT 150 mg/25 mg, film-coated
More informationWhich antihypertensives are more effective in reducing diastolic hypertension versus systolic hypertension? May 24, 2017
Which antihypertensives are more effective in reducing diastolic hypertension versus systolic hypertension? May 24, 2017 The most important reason for treating hypertension in primary care is to prevent
More informationNew Treatment Options for Diabetic Nephropathy patients. Prof. M. Burnier, Service of Nephrology and Hypertension CHUV, Lausanne, Switzerland
New Treatment Options for Diabetic Nephropathy patients Prof. M. Burnier, Service of Nephrology and Hypertension CHUV, Lausanne, Switzerland Diabetes and nephropathy Diabetic nephropathy is the most common
More informationALLHAT Role of Diuretics in the Prevention of Heart Failure - The Antihypertensive and Lipid- Lowering Treatment to Prevent Heart Attack Trial
1 ALLHAT Role of Diuretics in the Prevention of Heart Failure - The Antihypertensive and Lipid- Lowering Treatment to Prevent Heart Attack Trial Davis BR, Piller LB, Cutler JA, et al. Circulation 2006.113:2201-2210.
More information